Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 448

1.

PET/CT and brain MRI role in staging NSCLC: prospective assessment of the accuracy, reliability and cost-effectiveness.

Gkogkozotou VI, Gkiozos IC, Charpidou AG, Kotteas EA, Boura PG, Tsagouli SN, Syrigos KN.

Lung Cancer Manag. 2018 May 31;7(2):LMT02. doi: 10.2217/lmt-2018-0008. eCollection 2018 Jun.

2.

Crazy paving pattern as a rare radiological manifestation of peripheral T-cell lymphoma (PTCL) with lung involvement: A case report.

Gomatou G, Tzilas V, Kourti G, Lagou S, Bouros D, Syrigos K.

Respir Med Case Rep. 2018 Sep 26;25:253-256. doi: 10.1016/j.rmcr.2018.09.015. eCollection 2018.

3.

Hypoplastic thrombocytopenia and platelet transfusion: therapeutic goals.

Karakatsanis SJ, Papadatos SS, Syrigos KN.

Hosp Pract (1995). 2018 Nov 8:1-8. doi: 10.1080/21548331.2019.1546530. [Epub ahead of print]

PMID:
30409035
4.

Response to the letter to the editor: "New data for venous thromboembolism in patients with small cell lung cancer: A review".

Dimakakos E, Livanios K, Gkiozos I, Harpidou A, Ntalakou E, Kainis L, Syrigos K.

Phlebology. 2018 Nov 7:268355518812596. doi: 10.1177/0268355518812596. [Epub ahead of print] No abstract available.

PMID:
30403153
5.

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.

Toki MI, Mani N, Smithy JW, Liu Y, Altan M, Wasserman B, Tuktamyshov R, Schalper K, Syrigos KN, Rimm DL.

J Thorac Oncol. 2018 Dec;13(12):1884-1896. doi: 10.1016/j.jtho.2018.09.012. Epub 2018 Sep 26.

PMID:
30267840
6.

Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer.

Corredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos KN, Rimm DL, Yang M, Romero E, Schalper KA, Velcheti V, Madabhushi A.

Clin Cancer Res. 2018 Sep 10. pii: clincanres.2013.2018. doi: 10.1158/1078-0432.CCR-18-2013. [Epub ahead of print]

PMID:
30201760
7.

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.

Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J.

JAMA Oncol. 2018 Dec 1;4(12):e183486. doi: 10.1001/jamaoncol.2018.3486. Epub 2018 Dec 13.

PMID:
30177994
8.

Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.

Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT.

Oncologist. 2018 Nov;23(11):1372-1381. doi: 10.1634/theoncologist.2017-0530. Epub 2018 Aug 13.

PMID:
30104289
9.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

10.

Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping.

Papaxoinis G, Kotoula V, Giannoulatou E, Koliou GA, Karavasilis V, Lakis S, Koureas A, Bobos M, Chalaralambous E, Daskalaki E, Chatzopoulos K, Tsironis G, Pazarli E, Chrisafi S, Samantas E, Kaklamanos IG, Varthalitis I, Konstantara A, Syrigos KN, Pentheroudakis G, Pectasides D, Fountzilas G.

Med Oncol. 2018 May 31;35(7):101. doi: 10.1007/s12032-018-1160-1.

PMID:
29855806
11.

Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study.

Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C.

Anticancer Res. 2018 Jun;38(6):3735-3744. doi: 10.21873/anticanres.12654.

PMID:
29848736
12.

Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.

Vathiotis I, Dimakakos EP, Boura P, Ntineri A, Charpidou A, Gerotziafas G, Syrigos K.

Clin Appl Thromb Hemost. 2018 Nov;24(8):1347-1351. doi: 10.1177/1076029618777153. Epub 2018 May 27.

PMID:
29806470
13.

Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.

Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN.

J Thorac Oncol. 2018 Aug;13(8):1076-1082. doi: 10.1016/j.jtho.2018.04.031. Epub 2018 May 12. Review.

PMID:
29763666
14.

The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.

Magkrioti C, Oikonomou N, Kaffe E, Mouratis MA, Xylourgidis N, Barbayianni I, Megadoukas P, Harokopos V, Valavanis C, Chun J, Kosma A, Stathopoulos GT, Bouros E, Bouros D, Syrigos K, Aidinis V.

Cancer Res. 2018 Jul 1;78(13):3634-3644. doi: 10.1158/0008-5472.CAN-17-3797. Epub 2018 May 3.

PMID:
29724718
15.

Circulating tumor cells count as a predictor of survival in lung cancer.

Syrigos K, Fiste O, Charpidou A, Grapsa D.

Crit Rev Oncol Hematol. 2018 May;125:60-68. doi: 10.1016/j.critrevonc.2018.03.004. Epub 2018 Mar 7. Review.

PMID:
29650278
16.

Adjustable delivery of pro-angiogenic FGF-2 by alginate:collagen microspheres.

Ali Z, Islam A, Sherrell P, Le-Moine M, Lolas G, Syrigos K, Rafat M, Jensen LD.

Biol Open. 2018 Mar 12;7(3). pii: bio027060. doi: 10.1242/bio.027060.

17.

Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review.

Karvelas G, Roumpi A, Komporozos C, Syrigos K.

Hellenic J Cardiol. 2018 Jul - Aug;59(4):196-200. doi: 10.1016/j.hjc.2018.01.013. Epub 2018 Mar 29. Review.

18.

Nonpharmacologic Interventions for Improving Sleep Disturbances in Patients With Lung Cancer: A Systematic Review and Meta-analysis.

Papadopoulos D, Papadoudis A, Kiagia M, Syrigos K.

J Pain Symptom Manage. 2018 May;55(5):1364-1381.e5. doi: 10.1016/j.jpainsymman.2017.12.491. Epub 2018 Jan 6. Review.

PMID:
29309818
19.

Lung Metastasis From Fibrosarcomatous Dermatofibrosarcoma Protuberans of the Vulva: A Rare Case Report.

Vathiotis IA, Psichogiou E, Syrigos KN, Kotteas EA.

J Low Genit Tract Dis. 2018 Jan;22(1):85-87. doi: 10.1097/LGT.0000000000000360. No abstract available.

PMID:
29271862
20.

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.

Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA.

Clin Cancer Res. 2018 Apr 1;24(7):1562-1573. doi: 10.1158/1078-0432.CCR-17-2542. Epub 2017 Dec 4.

21.

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.

Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos K, Arrieta O, Prabhash K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Carter GC, Alexandris E, Garon EB.

Lung Cancer. 2017 Oct;112:126-133. doi: 10.1016/j.lungcan.2017.05.021. Epub 2017 Jun 3.

PMID:
29191585
22.

Anti-PD1/PDL1 induced psoriasis.

Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I, Aravantinos G, Syrigos K, Stratigos A.

Curr Probl Cancer. 2017 Nov - Dec;41(6):407-412. doi: 10.1016/j.currproblcancer.2017.10.003. Epub 2017 Oct 18.

PMID:
29096940
23.

The Role of Tinzaparin in Oncology.

Dimakakos EP, Vathiotis I, Syrigos K.

Clin Appl Thromb Hemost. 2018 Jul;24(5):697-707. doi: 10.1177/1076029617729215. Epub 2017 Oct 31. Review.

PMID:
29088922
24.

New data for venous thromboembolism in patients with small cell lung cancer: A review.

Dimakakos E, Livanios K, Gkiozos I, Charpidou A, Ntalakou E, Kainis L, Syrigos K.

Phlebology. 2018 Sep;33(8):517-522. doi: 10.1177/0268355517737670. Epub 2017 Oct 23. Review.

PMID:
29059023
25.

Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies.

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED.

J Thorac Oncol. 2017 Dec;12(12):1755-1765. doi: 10.1016/j.jtho.2017.09.1956. Epub 2017 Sep 27. Review.

26.

Thermal ablation may improve outcomes in patients with colorectal liver metastasis: a case-control study.

Poulou LS, Thanos L, Ziakas PD, Merikas E, Achimastos A, Gennatas C, Syrigos KN.

J BUON. 2017 May-Jun;22(3):673-678.

PMID:
28730773
27.

Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).

Christodoulou C, Kalogera-Fountzila A, Karavasilis V, Kouvatseas G, Papandreou CN, Samantas E, Varaki K, Papadopoulos G, Bobos M, Rallis G, Razis E, Goudopoulou A, Kalogeras KT, Syrigos KN, Fountzilas G.

J Neurooncol. 2017 Sep;134(2):443-451. doi: 10.1007/s11060-017-2548-z. Epub 2017 Jul 7.

PMID:
28687923
28.

Chromosome 7 Multiplication in EGFR-positive Lung Carcinomas Based on Tissue Microarray Analysis.

Tsiambas E, Mastronikolis NS, Lefas AY, Georgiannos SN, Ragos V, Fotiades PP, Tsoukalas N, Kavantzas N, Karameris A, Peschos D, Patsouris E, Syrigos K.

In Vivo. 2017 Jul-Aug;31(4):641-648.

29.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A.

Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.

30.

Optimizing diet and nutrition for cancer survivors: A review.

Mourouti N, Panagiotakos DB, Kotteas EA, Syrigos KN.

Maturitas. 2017 Nov;105:33-36. doi: 10.1016/j.maturitas.2017.05.012. Epub 2017 May 19. Review.

PMID:
28545906
31.

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.

Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, Herbst RS, Rimm DL.

Clin Cancer Res. 2017 Sep 1;23(17):5202-5209. doi: 10.1158/1078-0432.CCR-16-3107. Epub 2017 May 24.

32.

Therapeutic Challenges in Neuroendocrine Tumors.

Legakis I, Saif MW, Syrigos K.

Anticancer Agents Med Chem. 2017;17(7):902-919. doi: 10.2174/1871520617666170213113401. Review.

PMID:
28270063
33.

Proof of the quantitative potential of immunofluorescence by mass spectrometry.

Toki MI, Cecchi F, Hembrough T, Syrigos KN, Rimm DL.

Lab Invest. 2017 Mar;97(3):329-334. doi: 10.1038/labinvest.2016.148. Epub 2017 Jan 16.

34.

The use of novel oral anticoagulants in cancer patients with venous thromboembolism.

Karakatsanis SJ, Roumpi A, Syrigos KN.

Semin Oncol. 2016 Dec;43(6):655-665. doi: 10.1053/j.seminoncol.2016.11.009. Epub 2016 Nov 18. Review.

PMID:
28061983
35.

H1N1-Induced Venous Thromboembolic Events? Results of a Single-Institution Case Series.

Dimakakos E, Grapsa D, Vathiotis I, Papaspiliou A, Panagiotarakou M, Manolis E, Syrigos K.

Open Forum Infect Dis. 2016 Dec 20;3(4):ofw214. doi: 10.1093/ofid/ofw214. eCollection 2016 Oct.

36.

Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non-Small Cell Lung Cancer: A Case Report.

Syrigos K, Tsagouli S, Grapsa D.

Ann Intern Med. 2016 Dec 20;165(12):894-895. doi: 10.7326/L16-0137. No abstract available.

PMID:
27992901
37.

PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non-Small Cell Lung Cancer: Topic: Pathology.

Toki M, Cecchi F, Hembrough T, Syrigos K, Rimm D.

J Thorac Oncol. 2016 Nov;11(11S):S287. doi: 10.1016/j.jtho.2016.09.065. Epub 2016 Oct 28. No abstract available.

38.

EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.

Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL.

J Thorac Oncol. 2016 Nov;11(11):1901-1911. doi: 10.1016/j.jtho.2016.06.025. Epub 2016 Jul 20.

39.

Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges.

Matikas A, Syrigos KN, Agelaki S.

Clin Lung Cancer. 2016 Nov;17(6):507-516. doi: 10.1016/j.cllc.2016.05.021. Epub 2016 Jun 8. Review.

PMID:
27373516
40.

Can hair re-growth be considered an early clinical marker of treatment resistance to Hedgehog inhibitors in patients with advanced basal cell carcinoma? A report of two cases.

Soura E, Plaka M, Dessinioti C, Syrigos K, Stratigos AJ.

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1726-1729. doi: 10.1111/jdv.13754. Epub 2016 Jul 27.

PMID:
27461144
41.

Modeling Proteolytically Driven Tumor Lymphangiogenesis.

Lolas G, Jensen L, Bourantas GC, Tsikourkitoudi V, Syrigos K.

Adv Exp Med Biol. 2016;936:107-136.

PMID:
27739045
42.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.

J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.

43.

Incidence and implications of chemotherapy related hand-foot syndrome.

Nikolaou V, Syrigos K, Saif MW.

Expert Opin Drug Saf. 2016 Dec;15(12):1625-1633. Epub 2016 Oct 8. Review.

PMID:
27718746
44.

Genetic factors affecting patient responses to pancreatic cancer treatment.

Fotopoulos G, Syrigos K, Saif MW.

Ann Gastroenterol. 2016 Oct-Dec;29(4):466-476. Epub 2016 Jun 10. Review.

45.

P1.50: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects With Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy: Track: Supportive Care and Others.

Gascón P, Nagarkar R, Šmakal M, Syrigos K, Barrios CH, Sánchez JC, Zhang L, Henry DH, Fleishman A, De Oliveira Brandao C.

J Thorac Oncol. 2016 Oct;11(10S):S214-S215. doi: 10.1016/j.jtho.2016.08.072. Epub 2016 Sep 22. No abstract available.

46.

Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.

Skouras VS, Maragkos C, Grapsa D, Syrigos KN.

BioDrugs. 2016 Oct;30(5):421-439. Review.

PMID:
27670779
47.

Chromosomes 7/17 multiplication vs true polysomy: a crucial issue in lung and breast EGFR/HER2 dependent carcinoma cases.

Tsiambas E, Ragos V, Grapsa D, Kavantzas N, Karameris A, Stamatelopoulos A, Georgakopoulos G, Fotiades PP, Patsouris E, Syrigos K.

J BUON. 2016 May-Jun;21(3):752-3. No abstract available.

PMID:
27569103
48.

EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review.

Tsiambas E, Lefas AY, Georgiannos SN, Ragos V, Fotiades PP, Grapsa D, Stamatelopoulos A, Kavantzas N, Patsouris E, Syrigos K.

Pathol Res Pract. 2016 Aug;212(8):672-7. doi: 10.1016/j.prp.2016.06.005. Epub 2016 Jun 23. Review.

PMID:
27461822
49.

Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.

Papaxoinis G, Syrigos K, Saif MW.

Discov Med. 2016 May;21(117):391-402.

50.

New concepts in the treatment strategy of neuroendocrine tumors: the role of biotherapy.

Papaxoinis G, Syrigos K, Saif MW.

Discov Med. 2016 May;21(117):381-9. Review.

Supplemental Content

Loading ...
Support Center